These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38397992)

  • 61. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
    Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
    Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps.
    Kariyawasam HH; James LK; Gane SB
    Drug Des Devel Ther; 2020; 14():1757-1769. PubMed ID: 32440101
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
    Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
    Kilty SJ; Lasso A
    J Otolaryngol Head Neck Surg; 2022 Apr; 51(1):17. PubMed ID: 35468866
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
    Maspero JF; Katelaris CH; Busse WW; Castro M; Corren J; Chipps BE; Peters AT; Pavord ID; Ford LB; Sher L; Rabe KF; Rice MS; Rowe P; Lu Y; Harel S; Jagerschmidt A; Khan AH; Kamat S; Pirozzi G; Amin N; Ruddy M; Graham NMH; Mannent LP; Teper A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):527-539.e9. PubMed ID: 31351189
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
    Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
    Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The "real life" efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP.
    Campion NJ; Brugger J; Tu A; Stanek V; Brkic FF; Bartosik TJ; Liu DT; Hoehl BS; Gangl K; Eckl-Dorna J; Schneider S
    J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):56. PubMed ID: 37674253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study.
    Hopkins C; Buchheit KM; Heffler E; Cohen NA; Olze H; Khan AH; Msihid J; Siddiqui S; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2022; 15():767-773. PubMed ID: 35698581
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.
    Galletti C; Barbieri MA; Ciodaro F; Freni F; Galletti F; Spina E; Galletti B
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111387
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
    Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
    Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation.
    Trimarchi M; Vinciguerra A; Rampi A; Tanzini U; Nonis A; Yacoub MR; Bussi M
    Acta Otorhinolaryngol Ital; 2022 Dec; 42(6):538-544. PubMed ID: 36654520
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
    Bourdin A; Virchow JC; Papi A; Lugogo NL; Bardin P; Antila M; Halpin DMG; Daizadeh N; Djandji M; Ortiz B; Jacob-Nara JA; Gall R; Deniz Y; Rowe PJ
    Respir Med; 2022 Oct; 202():106938. PubMed ID: 36087550
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Experience with dupilumab in the treatment of chronic rhinosinusitis with nasal polyps].
    Boiko NV; Stagnieva IV; Lodochkina OE; Kurbatova NV
    Vestn Otorinolaringol; 2023; 88(4):46-53. PubMed ID: 37767590
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China.
    Li Y; Deng Z; Wen J; Ou C; Cen X; Liao Y; Zhang Q; Xie J
    Ann Med; 2024 Dec; 56(1):2311843. PubMed ID: 38316016
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)].
    Fomina DS; Fedosenko SV; Bobrikova EN; Chernov AA; Mukhina OA; Lebedkina MS; Karaulov AV; Nurtazina AY; Lysenko MA
    Ter Arkh; 2023 Sep; 95(7):568-573. PubMed ID: 38159007
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study.
    Bertlich M; Freytag S; Dombrowski T; Jurmeister P; Spiegel JL; Bertlich I; Ihler F; Weiss BG; Haubner F; Gröger M
    Medicine (Baltimore); 2022 Nov; 101(45):e31031. PubMed ID: 36397403
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
    Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.